LOPHIUS closed 2nd financing round and appoints Dr. Michael Lutz as new CEO

19-May-2010 - Germany

Lophius Biosciences announced that the company has successfully closed a 2nd round financing with a value of around 1,6 m EUR. The investment of S-Refit, the new lead investor, is strongly supplemented by follow up investments from existing investors High-Tech Gruenderfonds and Bayernkapital. The financing will be used to boost the development of the company with a strong focus on commercialization of existing diagnostic products and the generation of new tests based on the company´s proprietary technology platforms.

With immediate effect, Dr. Michael Lutz has been appointed as Lophius' new CEO. In this function, he replaces the existing managing directors PD Dr. Deml and Marc Akteries who will remain within the company in leading positions. Dr. Michael Lutz has significant expertise in building up and managing of innovative biotech companies. He supports Lophius since Sep. 2009 as coach and advisor. Before, Dr. Lutz was Global General Manager of Cogenics and CEO of Epidauros.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances